Xencor, Inc. (XNCR): Price and Financial Metrics


Xencor, Inc. (XNCR)

Today's Latest Price: $39.17 USD

0.31 (-0.79%)

Updated Oct 26 9:31am

Add XNCR to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 384 in Biotech

See all "A" rated Strong Buy stocks

XNCR Stock Summary

  • With a price/sales ratio of 31.55, Xencor Inc has a higher such ratio than 94.34% of stocks in our set.
  • In terms of twelve month growth in earnings before interest and taxes, Xencor Inc is reporting a growth rate of -261.97%; that's higher than only 7.12% of US stocks.
  • Revenue growth over the past 12 months for Xencor Inc comes in at -58.87%, a number that bests just 3.14% of the US stocks we're tracking.
  • Stocks that are quantitatively similar to XNCR, based on their financial statements, market capitalization, and price volatility, are NKTR, DNLI, ARVN, PRQR, and FATE.
  • XNCR's SEC filings can be seen here. And to visit Xencor Inc's official web site, go to www.xencor.com.

XNCR Stock Price Chart Interactive Chart >

Price chart for XNCR

XNCR Price/Volume Stats

Current price $39.17 52-week high $43.90
Prev. close $39.48 52-week low $19.35
Day low $38.68 Volume 1,866
Day high $39.21 Avg. volume 410,408
50-day MA $38.16 Dividend yield N/A
200-day MA $33.42 Market Cap 2.24B

Xencor, Inc. (XNCR) Company Bio


Xencor Inc. is a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of asthma and allergic diseases, autoimmune diseases and cancer. The company was founded in 1997 and is based in Monrovia, California.


XNCR Latest News Stream


Event/Time News Detail
Loading, please wait...

XNCR Latest Social Stream


Loading social stream, please wait...

View Full XNCR Social Stream

Latest XNCR News From Around the Web

Below are the latest news stories about Xencor Inc that investors may wish to consider to help them evaluate XNCR as an investment opportunity.

Xencor and MD Anderson Enter Strategic Collaboration to Advance Investigational XmAb® Drug Candidates

MONROVIA, Calif. & HOUSTON--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, and The University of Texas MD Anderson Cancer Center today announced a strategic collaboration to study investigational treatments for patients with a variety of cancer types. The parties will collaborate to design and execute additional clinical studies with Xencor’s portfolio of XmA

Business Wire | September 3, 2020

Xencor Inc (XNCR) CEO Bassil Dahiyat on Q2 2020 Results - Earnings Call Transcript

Xencor Inc (XNCR) Q2 2020 Results Conference Call August 04, 2020 4:30 PM ET Company Participants Charles Liles - Head of Investor Relations Bassil Dahiyat - President and Chief Executive Officer Allen Yeng - Chief Medical Officer John Desjarlais - Chief Scientific Officer John Kuch - Chief Financial Officer Conference...

SA Transcripts on Seeking Alpha | August 5, 2020

Xencor to Present at Upcoming Investor Conferences

MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, today announced that company management will participate in three upcoming conferences: BTIG Virtual Biotechnology Conference 2020 Date: Monday, August 10, 2020 Presentation Time: 12:00 p.m. ET / 9:00 a.m. PT 2020 Wedbush PacGrow Healthcare Virtual Conference Date: Wednesday, August 12, 2020 Pre

Business Wire | August 5, 2020

Xencor Reports Second Quarter 2020 Financial Results

MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, today reported financial results for the second quarter ended June 30, 2020 and provided a review of recent business and clinical highlights. "Late last week, the U.S. Food and Drug Administration approved MorphoSys' Monjuvi® (tafasitamab-cxix) for patients with an aggressive form of lymphoma, d

Business Wire | August 4, 2020

Xencor earns $25M milestone payment on FDA nod for lymphoma treatment

The FDA approval of MorphoSys' Monjuvi (tafasitamab-cxix) for treatment-resistant diffuse large B cell lymphoma ((DLBCL)) triggered a $25 million milestone payment and royalties, expected to be high single-digit-to-low double-digits, on net sales to licensor Xencor (XNCR), the company announced.Xencor out-licensed exclusive global rights to the humanized Fc-modified cytolytic anti-CD19 monoclonal antibody, which...

Seeking Alpha | August 2, 2020

Read More 'XNCR' Stories Here

XNCR Price Returns

1-mo 3.76%
3-mo 23.14%
6-mo 25.50%
1-year 8.06%
3-year 95.46%
5-year 246.33%
YTD 13.90%
2019 -4.89%
2018 64.96%
2017 -16.72%
2016 80.03%
2015 -8.85%

Continue Researching XNCR

Want to see what other sources are saying about Xencor Inc's financials and stock price? Try the links below:

Xencor Inc (XNCR) Stock Price | Nasdaq
Xencor Inc (XNCR) Stock Quote, History and News - Yahoo Finance
Xencor Inc (XNCR) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.8614 seconds.